Patients with treatable malignant diseases - including heart failure - are entitled to specialist care

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 2, 2005, Pages 207-209

  Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBULATORY CARE; CANADA; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; FOLLOW UP; GENERAL PRACTITIONER; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; MEDICAL SPECIALIST; METHODOLOGY; MORTALITY; NOTE; OUTCOMES RESEARCH; PATIENT CARE; PATIENT SELECTION; PROGNOSIS; SURVIVAL RATE; SYMPTOMATOLOGY;

EID: 12444279962     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.045307     Document Type: Note

References (19)

1. Ezekowitz JA, van Walraven C, McAlister FA, Armstrong PA, Kaul P. Impact of specialist follow-up in outpatients with congestive heart failure. CMAJ 2005;172(2):189-94.
2. Cleland JG, Khand A, Clark AC. The heart failure epidemic: Exactly how big is it? Eur Heart J 2001;22(8):623-6.
3. Johansson S, Wallander M-W, Ruigomez A, Rodriguez LAC. Incidence of newly diagnosed heart failure in UK general practice. Eur J Heart Fail 2001;2:225-31.
4. Roger VI, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA 2004;292(3):344-50.
5. Murphy NF, Simpson CR, McAlister FA, Stewart S, MacIntyre K, Kirkpatrick M, et al. National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. Heart 2004;90(10):1129-36.
6. Brown A, Cleland JG. Influence of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1998;19(7):1063-9.
7. Cleland JG, Gemmel I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999;1:229-41.
8. Khand AU, Gemmell I, Rankin AC, Cleland JG. Clinical events leading to the progression of heart failure: Insights from a national database of hospital discharges. Eur Heart J 2001;22:153-64.
9. Cleland JG, Swedberg K, Follath, et al, for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure Survey Programme: Survey on the Quality of Care Among Patients with Heart Failure in Europe. Part 1: Patient Characteristics and Diagnosis. Eur Heart J 2003;24:422-63.
10. Cleland JG, Lalukota K. How often should a patient with heart failure be seen by a specialist. A review of the evidence? Eur J Heart Fail [In press]
11. McAlister FA, Stewart S, Ferrua S, McMurray JJV. Multidisciplinary strategies for the management of heart failure patients at high risk for readmission. J Am Coll Cardiol 2004;44:810-9.
12. Gustafsson F, Arnold JMO. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J 2004;25 (1596):1604.
13. Louis AA, Turner T, Gretton M, Baksh A, Cleland JG. A systematic review of telemonitoring for the management of heart failure. Eur J Heart Fail 2003;5:583-90.
14. Fonarow GC. Heart failure disease management programs: not a class effect. Circulation 2004;110(23):3506-8.
15. Cleland JG, Freemantle N, Ball SG, Bonser RS, Camici PG, Chattopadhyay S, et al. The heart failure revascularization trial (HEART): rationale design and methodology. Eur J Heart Fail 2003;5(3):295-303.
16. Shelton RJ, Velavan P, Nikitin NP, Coletta AP, Clark AL, Rigby AS, Freemantle N, Cleland JGF. Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost effectiveness study. Eur J Heart Fail. In press.
17. Cleland JG. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 2002;4(3):243-7.
18. Louis AA, Balk AHMM, Janssens U, Cleland JGF. Telemonitoring for patients with heart failure at high risk for readmission and death. The Trans-European Network Home Monitoring Study (TEN-HMS). Eur J Heart Failure 2003;145(suppl) [abstract].
19. Cleland JG. Is aspirin "The Weakest Link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002;44:275-92.